

ADVENTRX PHARMACEUTICALS INC

Form 8-K

June 05, 2006

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15 (d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) June 5, 2006**

**ADVENTRX Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation)

**1-15803**

(Commission File Number)

**84-1318182**

(IRS Employer  
Identification No.)

**6725 Mesa Ridge Road, Suite 100**

**San Diego, California 92121**

(Address of principal executive offices) (Zip Code)

**(858) 552-0866**

(Company's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01. Other Events**

On June 5, 2006 the Company announced that it had presented median survival and an update of tumor response, time to tumor progression and safety data from its Phase II multi-center CoFactor clinical trial at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting.

The press release issued by the Company on June 5, 2006 with respect to this matter is included with this report as an exhibit.

**Item 9.01. Financial Statements and Exhibits.**

(d) The exhibit list required by this item is incorporated by reference to the Exhibit Index filed as part of this report.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ADVENTRX Pharmaceuticals, Inc.**

**By:** /s/ Evan M. Levine

**Name:** Evan M. Levine

**Title:** President & Chief Executive Officer

June 5, 2006

---

**Table of Contents**

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release of the Company dated June 5, 2006 re. Presentation of Positive Phase II CoFactor Results at ASCO Conference